A deliberative process with stakeholders, including policymakers, HTA experts, and endocrinologists, resulted in recommendations to offer CGMS for insulin-requiring T1DM patients at risk of severe hypoglycemic events. The gene discussed is INS; the disease is type 1 diabetes mellitus.